CANCER drug treatments are under scrutiny as a cause of soaring healthcare and claims costs. Current cancer patients will have to brace for changes.
Home Investments Fine-tuning MediShield Life: From 2022, cancer drug treatments must be in “positive...
- Advertisement -
Most Popular
DBS ‘categorically rejects’ S$1.3 billion claim by 1MDB-linked entities under liquidation
The bank has assessed that no provisions are required at this stage
